JP2010540449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540449A5 JP2010540449A5 JP2010525989A JP2010525989A JP2010540449A5 JP 2010540449 A5 JP2010540449 A5 JP 2010540449A5 JP 2010525989 A JP2010525989 A JP 2010525989A JP 2010525989 A JP2010525989 A JP 2010525989A JP 2010540449 A5 JP2010540449 A5 JP 2010540449A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antagonist
- medicament
- fragment
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97438207P | 2007-09-21 | 2007-09-21 | |
| US60/974,382 | 2007-09-21 | ||
| US8307108P | 2008-07-23 | 2008-07-23 | |
| US61/083,071 | 2008-07-23 | ||
| PCT/US2008/076954 WO2009039337A2 (en) | 2007-09-21 | 2008-09-19 | Inhibition of angiogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540449A JP2010540449A (ja) | 2010-12-24 |
| JP2010540449A5 true JP2010540449A5 (https=) | 2011-11-04 |
| JP5615709B2 JP5615709B2 (ja) | 2014-10-29 |
Family
ID=40030248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525989A Expired - Fee Related JP5615709B2 (ja) | 2007-09-21 | 2008-09-19 | 脈管形成の阻害 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9284369B2 (https=) |
| EP (1) | EP2203479B1 (https=) |
| JP (1) | JP5615709B2 (https=) |
| KR (1) | KR101578945B1 (https=) |
| CN (1) | CN102037015B (https=) |
| AR (1) | AR068532A1 (https=) |
| AU (1) | AU2008302214B2 (https=) |
| CA (1) | CA2700276A1 (https=) |
| CL (1) | CL2008002782A1 (https=) |
| CO (1) | CO6270370A2 (https=) |
| ES (1) | ES2568881T3 (https=) |
| IL (1) | IL204502A (https=) |
| MX (1) | MX2010003013A (https=) |
| NZ (1) | NZ584787A (https=) |
| PE (1) | PE20091197A1 (https=) |
| RU (2) | RU2471498C2 (https=) |
| TW (1) | TWI457349B (https=) |
| WO (1) | WO2009039337A2 (https=) |
| ZA (1) | ZA201001868B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL368972A1 (en) * | 2001-08-29 | 2005-04-04 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
| JP4912144B2 (ja) | 2003-03-12 | 2012-04-11 | ジェネンテック， インコーポレイテッド | 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用 |
| CA2679867A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
| RU2567803C2 (ru) * | 2009-07-31 | 2015-11-10 | Дженентек, Инк. | ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF |
| DK2488554T3 (da) | 2009-10-14 | 2019-09-02 | Humanigen Inc | Antistoffer mod epha3 |
| RU2559542C2 (ru) | 2009-12-23 | 2015-08-10 | Дженентек, Инк. | Антитела против bv8 и их применение |
| WO2011103389A1 (en) | 2010-02-19 | 2011-08-25 | Cornell University | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| JP6187777B2 (ja) | 2011-06-13 | 2017-08-30 | シーエスエル、リミテッド | Ｇ−ｃｓｆｒに対する抗体およびその使用 |
| CA2842481A1 (en) * | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
| WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
| WO2013148285A1 (en) * | 2012-03-30 | 2013-10-03 | The General Hospital Corporation | Methods of inhibiting cell proliferation |
| TWI498425B (zh) * | 2013-01-08 | 2015-09-01 | Nat Univ Tsing Hua | 層析濾紙型酵素連結免疫吸附分析法 |
| WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
| KR102359396B1 (ko) * | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| CN104237223B (zh) * | 2014-10-08 | 2017-04-12 | 江苏奥赛康药业股份有限公司 | 测定铁‑碳水化合物络合物中不稳定铁含量的方法 |
| CN104587469A (zh) * | 2015-01-19 | 2015-05-06 | 马洁 | G-csf拮抗剂在治疗慢性炎症、预防炎症相关肿瘤中的应用 |
| TWI746491B (zh) * | 2015-12-03 | 2021-11-21 | 財團法人國家衛生研究院 | 異質雙聚體型血管內皮生長因子及其應用 |
| WO2018108862A1 (en) * | 2016-12-12 | 2018-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer |
| CA3081770A1 (en) | 2017-11-29 | 2019-06-06 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| FI3743091T3 (fi) | 2018-01-26 | 2025-01-03 | Univ California | Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita |
| WO2019178645A1 (en) | 2018-03-23 | 2019-09-26 | Csl Limited | Method of treating asthma |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
| US12583929B2 (en) | 2020-06-04 | 2026-03-24 | CSL Innovation Pty Ltd | Method of treating acute respiratory distress syndrome |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| KR20260036321A (ko) | 2023-07-05 | 2026-03-16 | 씨에스엘 이노베이션 피티와이 엘티디 | 겸상적혈구병의 합병증을 치료하거나 예방하는 방법 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| PL368972A1 (en) * | 2001-08-29 | 2005-04-04 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| JP4912144B2 (ja) * | 2003-03-12 | 2012-04-11 | ジェネンテック， インコーポレイテッド | 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用 |
| CN1802169A (zh) * | 2003-03-12 | 2006-07-12 | 健泰科生物技术公司 | Bv8和/或EG－VEGF促进造血的用途 |
| MXPA05012723A (es) * | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| CA2622575A1 (en) * | 2005-09-13 | 2007-03-22 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
| ITRM20070182A1 (it) * | 2007-04-03 | 2008-10-04 | Univ Roma | Antagonisti dei recettori delle prochineticine derivati di essi e loro uso |
-
2008
- 2008-09-17 CL CL2008002782A patent/CL2008002782A1/es unknown
- 2008-09-19 MX MX2010003013A patent/MX2010003013A/es active IP Right Grant
- 2008-09-19 WO PCT/US2008/076954 patent/WO2009039337A2/en not_active Ceased
- 2008-09-19 ES ES08832515.4T patent/ES2568881T3/es active Active
- 2008-09-19 CA CA2700276A patent/CA2700276A1/en not_active Abandoned
- 2008-09-19 KR KR1020107008635A patent/KR101578945B1/ko not_active Expired - Fee Related
- 2008-09-19 PE PE2008001642A patent/PE20091197A1/es not_active Application Discontinuation
- 2008-09-19 US US12/679,257 patent/US9284369B2/en not_active Expired - Fee Related
- 2008-09-19 AU AU2008302214A patent/AU2008302214B2/en not_active Ceased
- 2008-09-19 CN CN200880117292.XA patent/CN102037015B/zh not_active Expired - Fee Related
- 2008-09-19 TW TW097136179A patent/TWI457349B/zh not_active IP Right Cessation
- 2008-09-19 NZ NZ584787A patent/NZ584787A/xx not_active IP Right Cessation
- 2008-09-19 EP EP08832515.4A patent/EP2203479B1/en active Active
- 2008-09-19 RU RU2010115755/15A patent/RU2471498C2/ru not_active IP Right Cessation
- 2008-09-19 JP JP2010525989A patent/JP5615709B2/ja not_active Expired - Fee Related
- 2008-09-22 AR ARP080104117A patent/AR068532A1/es unknown
-
2010
- 2010-03-15 IL IL204502A patent/IL204502A/en not_active IP Right Cessation
- 2010-03-16 ZA ZA2010/01868A patent/ZA201001868B/en unknown
- 2010-04-14 CO CO10043417A patent/CO6270370A2/es not_active Application Discontinuation
-
2012
- 2012-09-19 RU RU2012140185/15A patent/RU2012140185A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540449A5 (https=) | ||
| RU2010115755A (ru) | Ингибирование ангиогенеза | |
| Kienast et al. | Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy | |
| Li et al. | Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects | |
| CN108348575B (zh) | 用于治疗癌症或血管生成相关疾病的药物组合物和融合蛋白的用途 | |
| JP6519090B2 (ja) | 血管内皮成長因子融合タンパク質 | |
| EP3553083A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| Lee et al. | Options for second-line treatment in metastatic colorectal cancer | |
| WO2016122996A1 (en) | Vegfa/ang2 compounds | |
| JP2014522828A (ja) | Ｉｒｓ−１およびｖｅｇｆの阻害剤を含む組成物 | |
| Bagley et al. | sFLT01: a novel fusion protein with antiangiogenic activity | |
| US12409178B2 (en) | Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors | |
| Bocci et al. | The possible role of chemotherapy in antiangiogenic drug resistance | |
| RU2740849C2 (ru) | Способ, включающий фиксированное дробное дозирование цедираниба | |
| IL295093A (en) | Combination therapy for treatment of cancer and cancer metastasis | |
| TWI895563B (zh) | 用於治療實性瘤之包含ｋｒａｓｇ１２ｃ抑制劑及ｅｇｆｒ抑制劑之組成物及方法 | |
| Kou et al. | A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin | |
| Grela-Wojewoda et al. | De-escalation of the systemic therapy in advanced colorectal cancer–justified clinical practice from the point of view of efficiency and safety | |
| Oh et al. | Antibodies that inhibit specific cellular pathways in gastric cancer | |
| Boruta et al. | PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy | |
| RINI et al. | Ligand-Binding Agents | |
| Wainberg et al. | Using an anti-VEGF monoclonal antibody to treat cancer | |
| Toh et al. | First-line treatment of metastatic breast cancer: Focus on bevacizumab. |